| Project/Area Number |
24241030
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Quantum beam science
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Shinohara Atsushi 大阪大学, 理学(系)研究科(研究院), 教授 (60183050)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAHASHI Naruto 大阪大学, 大学院理学研究科, 講師 (00197162)
KASANATSU Yoshitaka 大阪大学, 大学院理学研究科, 助教 (70435593)
YOSHIMURA Takashi 大阪大学, ラジオアイソトープ総合センター, 教授 (90323336)
NINOMIYA Kazuhiko 大阪大学, 大学院理学研究科, 助教 (90512905)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HATANAKA Kichiji 大阪大学, 核物理研究センター, 教授 (50144530)
HATAZAWA Jun 大阪大学, 大学院医学系研究科, 教授 (70198745)
KANAI Yasukazu 大阪大学, 大学院医学系研究科, 助教 (60397643)
|
|---|
| Project Period (FY) |
2012-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥47,970,000 (Direct Cost: ¥36,900,000、Indirect Cost: ¥11,070,000)
Fiscal Year 2015: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2014: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2013: ¥11,570,000 (Direct Cost: ¥8,900,000、Indirect Cost: ¥2,670,000)
Fiscal Year 2012: ¥27,950,000 (Direct Cost: ¥21,500,000、Indirect Cost: ¥6,450,000)
|
|---|
| Keywords | 医療用放射性核種 / 分子イメージング / サイクロトロン / 核医学 / PET / RI内用療法 / アスタチン / テクネチウム / アルファ線内用療法 / 核医学用RI製造 / 加速器 / がん診断用イメージング核種 / 核医学用RI製造装置 / がん診断用核種 / 抗がん剤 / シスプラチン / α線内用療法 / 放射性同位元素 / α放射体 |
|---|
| Outline of Final Research Achievements |
The stable supply of the radioactive isotopes (RI) is essential for medicine and basic science that use the RI. However, we have no systematic RI production and supply system in Japan. In this study, we have developed the large scale irradiation apparatus for RI production using cyclotron beam and prepared 124-I, 62-Zn, and 191-Pt as new probe RI for PET and SPECT. These RI will take an important role for early diagnostics and therapy for cancer, drug development, as well as basic research of medicine and pharmacy. We also recently focus on development of targeted alpha therapy using 211-At, especially, for treatment for recalcitrant tumor. Furthermore we have developed purification method for 99m-Tc produced by an accelerator to confirm the domestic supply system for 99m-Tc.
|
